Centrinone-B

CAS No. 1798871-31-4

Centrinone-B( —— )

Catalog No. M33313 CAS No. 1798871-31-4

Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor with a Ki of 0.59 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Centrinone-B
  • Note
    Research use only, not for human use.
  • Brief Description
    Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor with a Ki of 0.59 nM.
  • Description
    Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM.
  • In Vitro
    Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM. Centrinone-B slightly binds to Aurora A and Aurora B, with Kis of 1239 nM and 5597.14 nM. Centrinone-B (LCR-323) exhibits >1000-fold selectivity for Plk4 over Aurora A/B in vitro and does not affect cellular Aurora A or B substrate phosphorylation at concentrations that deplete centrosomes. Centrinone-B (LCR-323) (0-200 nM) significantly decreases cell viability of PLK4-centriole conjunction melanoma cell lines except p53 mutant SK-MEL-28, and this effect is via inhibition of PLK4. Inhibition of PLK4 by Centrinone-B (LCR-323) also induces apoptosis in human melanoma cell lines.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PLK
  • Recptor
    PLK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1798871-31-4
  • Formula Weight
    631.67
  • Molecular Formula
    C27H27F2N7O5S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (39.58 mM; Ultrasonic )
  • SMILES
    COc1c(Nc2cc(C)[nH]n2)nc(Sc2ccc(cc2F)S(=O)(=O)Cc2cccc(c2F)[N+]([O-])=O)nc1N1CCCCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wong YL, et al. Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science. 2015 Jun 5;348(6239):1155-60.?
molnova catalog
related products
  • Cyclapolin 9

    Cyclapolin 9 is a selective, potent, and ATP-competitive inhibitor of polo-like kinase 1 (PLK1) with an IC50 of 500 nM, and has not shown activity against other kinases.

  • Volasertib

    Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC50 of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively.

  • Epimedin A

    Epimedin A has anti-osteoporosis activities in vivo.